anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Focus groups will be conducted at two Adolescent Medicine Trials Unit (AMTU) sites and will guide the selection of the intervention content areas and the development of the intervention manual. The intervention aims to increase participation in health promoting behaviors and improve self-worth and self-concept among HIV-positive B-YMSM. Specifically, the intervention aims to address the following health promoting behaviors: 1) increasing engagement in HIV treatment; 2) improving medication adherence; 3) reducing sexual risk behaviors; 4) reducing substance use behaviors; and 5) increasing HIV status disclosure.

Based on reviews of ATN 070 data and existing related interventions (ATN 068, ATN 073, Young Warriors, HLS), draft components of the intervention curriculum for B-YMSM will be developed. Four focus groups will then be convened (two per AMTU) with HIV-positive B-YMSM to a) obtain input on the draft intervention curriculum, b) refine intervention components, and c) examine psychosocial factors that may mediate or moderate the intervention effect. The focus groups will be implemented using a "Rapid Approach" which allows for a focus on key areas of inquiry by asking fewer questions and focusing on targeted responses of focus group participants. All focus groups will be digitally recorded and transcribed. The transcripts will be reviewed and data analyzed using a phenomenological approach; protocol team members and members of two Youth Advisory Boards (YABs), which will include youth who are existing members of ATN site CABs as well as youth recruited from other local agencies and organizations), will work on the analysis of the data.
PURPOSE:To provide the titled stimulant containing docosahexaenoic acid or its derivative. CONSTITUTION:The objective agent for stimulating lipoxygenase metabolism contains docosahexaenoic acid having lipoxygenase stimulating activity (existing in lipid of aquatic animal oil, agar such as marine chlorella, yolk lipid, and blood cell and liver of mammal) or its derivative (e.g. fat-soluble compound such as triglycerides, ethyl esters and phospholipids or water-soluble compound such as alpha-amino acid derivatives). The agent is used especially for prevention and remedy of diseases caused by insufficient production of lipoxygenase metabolism product. The oil-soluble active component is dissolved in various oil-soluble substances and used as a soft capsule, etc., and the water-soluble active component can be converted to injection simply by dissolving in distilled water for injection. A fat infusion useful as a preventive and remedy can be prepared by adjusting the amounts of oil and glycerol.
ZEPZELCA can cause myelosuppression. 

In clinical studies of 554 patients with advanced solid tumors receiving ZEPZELCA [see Adverse Reactions (6.1)], Grade 3 or 4 neutropenia occurred in 41% of patients, with a median time to onset of 15 days and a median duration of 7 days. Febrile neutropenia occurred in 7% of patients. Sepsis occurred in 2% of patients and was fatal in 1% (all cases occurred in patients with solid tumors other than SCLC). Grade 3 or 4 thrombocytopenia occurred in 10%, with a median time to onset of 10 days and a median duration of 7 days. Grade 3 or 4 anemia occurred in 17% of patients.

Administer ZEPZELCA only to patients with baseline neutrophil count of at least 1,500 cells/mm3 and platelet count of at least 100,000/mm3. Monitor blood counts including neutrophil count and platelet count prior to each administration. For neutrophil count less than 500 cells/mm3 or any value less than lower limit of normal, the use of G-CSF is recommended. Withhold, reduce the dose, or permanently discontinue ZEPZELCA based on severity [see Dosage and Administration (2.2)].
Infants, who were expected to be ≥2000 grams at birth (i.e. full-term) at time of enrollment, born to women with HIV-1 infection who received RAL 400 mg twice daily for at least two weeks prior to delivery and continued to receive ARVs during labor. The group also includes the mothers of these infants.
Type 2 diabetes mellitus (T2DM) has an increasing worldwide incidence. Insulin resistance is a key pathophysiological process in the development of hyperglycemia in patients with T2DM. Disruption of circadian synchrony leads to insulin resistance. Animal studies and post-mortem human brain studies suggest that the master brain clock in the hypothalamic suprachiasmatic nucleus (SCN) plays a role in the development of insulin resistance. Up to now, no-one has investigated whether the in vivo activity rhythm of the SCN is affected in patients with insulin resistance. The investigators hypothesize that the master brain clock has an important role in the development of human insulin resistance.
Objective: To observe the recurrence condition of hepatitis B in different risk groups after liver transplantation in an attempt to provide useful information on whether to discontinue hepatitis B immunoglobulin (HBIG) in the future at an early stage. Methods: The patient population was divided into high, low-risk, and special groups [especially primary hepatocellular carcinoma (HCC)] according to the guidelines for the prevention and treatment of hepatitis B recurrence after liver transplantation. The recurrence condition and risk factors in this population were observed for hepatitis B. Measurement data were analyzed using a t-test and a rank-sum test. Count data were compared using a χ(2) test between groups. Results: This study finally included 532 hepatitis B-related liver transplant cases. A total of 35 cases had HBV recurrence after liver transplantation, including 34 cases that were HBsAg positive, one case that was HBsAg negative, and 10 cases that were hepatitis B virus (HBV) DNA positive. The overall HBV recurrence rate was 6.6%. The recurrence rate of HBV was 9.2% and 4.8% in the high- and low-risk HBV DNA positive and negative groups before surgery (P = 0.057). Among the 293 cases diagnosed with HCC before liver transplantation, 30 had hepatitis B recurrence after surgery, with a recurrence rate of 10.2%. The independent related factors for the recurrence of hepatitis B in patients with HCC after liver transplantation were HCC recurrence (HR =181.92, 95%CI 15.99~2 069.96, P < 0.001), a high postoperative dose of mycophenolate mofetil dispersible tablets (MMF) ( HR =5.190, 95%CI 1.289~20.889, P = 0.020), and a high dosage of HBIG (HR = 1.012, 95%CI 1.001~1.023, P = 0.035). Among the 239 cases who were non-HCC before liver transplantation, five cases (recurrence rate of 2.1%) arouse postoperative hepatitis B recurrence. Lamivudine was used in all cases, combined with on-demand HBIG prophylaxis after surgery. There was no hepatitis B recurrence in non-HCC patients who treated with entecavir combined with HBIG after surgery. Conclusion: High-barrier-to-resistance nucleotide analogues combined with long-term HBIG have a good effect on preventing the recurrence of hepatitis B after liver transplantation. The discontinuation of HBIG may be considered at an early stage after administration of a high-barrier-to-resistance nucleotide analogue in low-risk patients. Domestically, the HBV infection rate is high, so further research is still required to explore the timing of HBIG discontinuation for high-risk patients, especially those with HCC.
Embodiments of a finishing powder of this disclosure include a rice powder and an iron-oxide pigment, with no talc or parabens, that eliminates transfer of wet or sticky spray tan bronzer to clothing, hands, or between opposing folds or creases of skin. The finishing powder may be applied full body—for example 85% to 95% of total body surface area—by way of a brush, being too thick in its consistency to spray. The powder may be blown from the brush to the body. An amount of the mixture applied to a user may be in a range ¾ teaspoon to 2¼ teaspoon. The powder immediately coats the spray tanning solution and remains dry to the touch. Because of its thicker consistency, the powder does not dissipate and remains on the skin up to 24 hours or until the user showers.
The invention discloses a traditional Chinese medicine pressurized spray for treating skin disorders or mucosa orifice diseases. The pressurized spray is prepared from the following raw material medicines in parts by weight: 250 to 500 parts of herba euphorbiae humifusae, 50 to 250 parts of cortex dictamni, 50 to 250 parts of clove, 25 to 175 parts of tokyo violet herb, 25 to 175 parts of rhizoma dryopteris crassirhizomae, 25 to 175 parts of purslane and 5 to 50 parts of borneol. The invention also provides a detection method thereof. The method comprises the following steps: using a thin-layer chromatography to qualitatively identify the herba euphorbiae humifusae, the clove, the tokyo violet herb and the cortex dictamni, and using an HPLC (high performance liquid chromatography) to determine the content of the herba euphorbiae humifusae. The pressurized spray provided by the invention has unique curative effects on early stage pain and after pain of herpes. The preparation has the efficacies of clearing heat and removing toxicity, dispelling wind and arresting itching and activating meridians to stop pain. The preparation has stronger actions of antivirus and broad-spectrum antibacterial. The pressurized spray can be used for treating various skin and mucosaorifice diseases, such as herpes zoster, herpes labialis, varicella, beriberi, vaginitis and the like.
PURPOSE:To provide the titled preventing agent containing an acetyl-salicylic acid salt as an active component and effective at a low dose. CONSTITUTION:The objective agent for preventing peritoneal adhesion can be produced by dissolving an acetylsalicylic acid salt (preferably lysine salt, especially DL-lysine salt) at a concentration of 5-20W/V%, preferably 10W/V% in use and, if necessary, adding other drug-active component thereto. Acetylsalicylic acid salt is easily soluble in water and is especially useful as a liquid agent. The agent is administered at a dose of 100-1,000mg in terms of acetylsalicylic acid (10-50ml of liquid) preferably by peritoneal infusion s an injection, etc. EFFECT:The agent is effective in preventing perinoneal adhesion after abdominal operation. It can be directly administered to abdominal cavity as a liquid agent. It gives no serious side effect and has high safety.
OBJECTIVES: The great saphenous vein is the lower limb's longest and thickest-walled superficial vein. Its anatomy is complex, while its anatomical variations are widespread. This study aimed to illustrate the anatomy and variations of the great saphenous vein at the saphenofemoral junction.
METHODS: The study was conducted on 75 fresh-frozen cadaveric lower limbs. Cadavers with evidence of prior leg surgery or trauma and any congenital abnormality or gross deformity were excluded. The saphenofemoral junction was studied in detail with emphasis on the number, incidence, draining pattern of tributaries, and duplication of the great saphenous vein.
RESULTS: Out of the 75 cadaveric lower limbs, 57.3% were obtained from males, and 42.7% were obtained from females. The mean age of the cadaveric lower extremities was 66.6 years (range 42-91). The number of tributaries at the saphenofemoral junction varied from 0 to 7, with a mean of 3.8. The most frequent number of branches was 4-5 in 61.3% of cases. The most consistent tributary was the superficial external pudendal vein, while the posterior accessory great saphenous vein was the least frequent tributary. 80% of the branches drained into the saphenofemoral junction directly (53.3%) or by a common trunk (26.7%%). The most frequent common trunk was the superficial epigastric and superficial circumflex iliac vein (10.7%). The rest 20% of the tributaries drained directly into the common femoral vein. The commonest branch reaching the common femoral vein was the superficial external pudendal vein (10.7%). Duplication of the great saphenous vein was observed in 2.7% of the cases.
CONCLUSIONS: There is a significant variation of tributaries at the saphenofemoral junction regarding the number, incidence, draining pattern of branches, and duplication of the great saphenous vein.
PURPOSE: A composition containing Lilium candidum extract and carriers is provided to suppress melanogenesis and to enhance skin lightening effect. CONSTITUTION: A skin lighetening method comrises a step of applying a composition containing Lilium candidum whole plant extract, flower extract, stem extract, leaf extract, or combination thereof onto the skin. The composition contains polyunsaturated fatty acid with chemical formula I(R-COOH). In chemical formula I, R is -(CH2)z-(CH=CH-CH2)n-(CH2)m-CH3. The extract contains a part of polyunsaturated fatty acid. The extract contains 40-95 % of the polyunsaturated fatty acid and polysaccharides, oligosaccharides, disaccharides, or combination thereof.
PURPOSE:To obtain the titled antitumor agent containing seeds of betel palm tree, Rhei Rhizoma, talc, Bezoar Orientale and Hoelen as materials. CONSTITUTION:The following materials are prepared. A dried material 1 of sliced pieces obtained from raw seeds of betel palm tree; a dried material 2 of cut pieces obtained by drying Rhei Rhizoma in the sun for about 2 days and aging by burying in earth; a fine powder 3 obtained by heating talc with mild heating power, such as charcoal fire, and burning the talc to assume yellow color; a fine powder 4 prepared by burning Bezoar Orientale on an inorganic pottery, such as red brick, with a mild heating power to remove cholesterol and pulverizing the resultant material a fine powder 5 obtained by drying cut pieces of raw Hoelen in the sun, adding raw pineapple juice, fermenting the resultant pieces, then drying the fermented pieces in the sun and pulverizing the dried pieces. Water is then boiled and the dried material 1 is added thereto and boiled down at 95-98 deg.C. The dried material 2 is subsequently added thereto and boiled down. The fine powder 3 is further added and the obtained blend is stirred and filtered. The fine powder 4 is then added into the obtained hot filtrate and stirred. The fine powder 5 is subsequently added and stirred to afford a blend, which is then dried in the sun and pulverized into fine particulate form to provide the aimed low-molecular vegetable antimalignant tumor agent.
Mechanisms are provided for performing sequential multi-modal communication with patients. The mechanisms generate a patient registry comprising a plurality of patient registry records, each patient registry record being associated with a corresponding patient and comprising personal and medical information about the corresponding patient. The mechanisms collect, for each patient registry record, first data regarding treatment of the corresponding patient and second data regarding communications made with the corresponding patient. The mechanisms determine, based on analysis of the first data and second data associated with each of the patient registry records, a sequence of modes of communication that is most likely to result in a successful treatment of patients. The mechanisms initiate a plurality of communications with a patient of interest using the determined sequence of modes of communication based on the results of the determination. The plurality of communications follow the sequence specified in the sequence of modes of communication.
We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
Gallbladder cancer (GBC) is a neglected disease with huge potential for prevention. This study aims at significantly improving the accuracy of risk estimation and early detection of GBC by identifying and adequately considering geographical, environmental, lifestyle, ethnic, gender and molecular differences. The investigators plan to generate the information needed to establish and refine current prevention programmes, including the primary, secondary and tertiary prevention of GBC. The investigators will (1) build a unique European-Latin American GBC biorepository integrated into a tailored IT platform, (2) identify, validate and functionally characterize novel GBC biomarkers, (3) develop a multifactorial risk score that integrates established and newly identified epidemiological and molecular risk factors, (4) improve the understanding of the causal mechanisms that link lifestyle, cultural and behavioural factors to GBC development, (5) unravel novel opportunities for the targeted therapy of incidental GBC, (6) exploit existing and newly generated epidemiological and multi-omics data to improve the accuracy of GBC risk prediction and (7) contribute to the training of the next generation of Latin American researchers in precision medicine for GBC. The generated information will permit identification of individuals at high GBC risk, guiding surveillance and individual decisions on the possible benefit of preventive gallbladder removal in regions of low and high GBC incidence. Novel data on genomic alterations in incidental GBC will pave the way towards implementation of future clinical trials. The planned European-Latin American GBC biorepository and IT platform will constitute a prime resource for translational research on individualized prevention, personalized early detection and targeted therapy of GBC. The participation in our project of representatives of health authorities, patients and the industry guarantee the efficient incorporation of project results into national health policies.

The study protocol has been approved by the Comité de Protection des Personnes, France, the ethics committees of Servicio de Salud Metropolitano Oriente, Servicio de Salud Metropolitano Sur Oriente and Servicio de Salud Metropolitano Central in Santiago de Chile, Servicio de Salud Coquimbo in Coquimbo, Chile, Servicio de Salud Maule in Talca, Chile, Universidad Católica del Maule in Talca, Chile, Servicio de Salud Concepción in Concepción, Chile, Servicio de Salud Araucanía Sur in Temuco, Chile, Servicio de Salud Valdivia in Chile, Centro de Bioética Universidad del Desarrollo and Clínica Alemana de Santiago in Santiago de Chile, Unidad de Investigación Hospital San Juan de Dios in Santiago de Chile, the Medical Faculties of Universidad de Chile and Pontificia Universidad Católica de Chile, Facultad de Medicina, Universidad Mayor de San Simón, Bolivia, Comité Provincial de Ética de Investigación de la Provincia de Jujuy, Argentina, and Comité de ética e Investigación del Instituto Nacional de Enfermedades Neoplásicas, Peru.
Participants in Part 2 will only receive single dose of Treatment B2 then Treatment C2 followed by Treatment A2 on Day 1 of the treatment period (Days 1 to 4). Successive treatment periods will be separated by a washout period of 14 days (+/- 1 day).
The need for non-invasive evaluation of ICP is an active area of study. The current gold standard is intraventricular or intraparenchymal catheters but these are invasive, expensive, and require sedation; and thus the need for an effective non-invasive screening tool. The utility of funduscopy in identifying processes affecting ICP has long been recognized, i.e. papilledema, ocular venous engorgement, blurring of the optic disk. Studies have demonstrated that funduscopy may have a role in the qualitative assessment of increased ICP as a highly sensitive test. However, conventional bedside funduscopy does not allow for image capture and may necessitate pupillary dilation. Portable fundus cameras address these issues, allowing image capture and storage and the potential for non-mydriatic imaging, i.e. imaging without dilation of eyes. And as demonstrated in a recent study, portable fundus cameras are efficient (median exam time was 3 minutes and 24 seconds in a pediatric Emergency Department).

Additionally, ICP screening in asymptomatic patients remains limited. Patients being treated with medications for acne, specifically tetracyclines (e.g. minocycline and doxycycline), retinol, and isotretinol, are at particular risk for increased ICP but often are not identified until they are symptomatic (i.e. headaches, visual loss, papilledema). Symptom onset has been documented from 2 weeks up to 1 year from drug initiation. The percentage of patients with subclinical asymptomatic disease is unclear. This study would allow us to describe the presence of subclinical disease in our population and the role/utility of routine non-invasive screening methods.
The invention relates to indole derivatives having an inhibiting effect on phenol oxidases. Melanin-related hyperpigmentation of skin is a considerable medical and therapeutic problem.  The current possibilities for therapeutic effects, in addition to invasive methods, particularly the insertion of decolorants, are limited.  The invention also relates to the increased need for agents and substances for treating melanin-related hyperpigmentation.  The amino acid tryptophane (as an L or D isomer or also as a racemate) is provided for a particular subpopulation of the yeast type Melassezia, particularly the yeast species Melassezia furfur, as a predominant nitrogen source, and compounds are isolated from the yeast conditioned in such a manner, said compounds represent potent inhibitors of phenol oxidases.  The novel indole derivatives isolated from Melassezia is particularly suitable to be used as substances for producing medicaments for treating  melanin-related hyperpigmentation.
Fluticasone propionate lotion USP, 0.05% contains fluticasone propionate USP S-Fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-3-oxo-17α-propionyloxyandrosta-1,4-diene-17β-carbothioate, a synthetic fluorinated corticosteroid, for topical use. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.

Chemically, fluticasone propionate USP is C25H31F3O5S. It has the following structural formula:

Fluticasone propionate USP is a white or almost white powder with a molecular weight of 500.6 g/mol. It is freely soluble in dimethylformamide; slightly soluble in alcohol; sparingly soluble in acetone and in dichloromethane; insoluble in water.

Each gram of fluticasone propionate lotion USP contains 0.5 mg fluticasone propionate USP in a base of cetostearyl alcohol, polyoxyl 20 cetostearyl ether, citric acid anhydrous, dimethicone 360, isopropyl myristate, light mineral oil, propylene glycol, sodium citrate anhydrous, sorbitan monostearate, and purified water, with imidurea, methylparaben, and propylparaben as preservatives.
Debridement of the pilonidal cyst through pits was performed in this group. After the removal of hair and necrotic tissues through pits, the surgical site was covered with a simple gauze dressing for 1 day. Patients were allowed to return to work and sit freely on the day of surgery.